发明名称 |
Treatment of BDNF-related disorders using laquinimod |
摘要 |
This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject. This application also provides for a pharmaceutical preparation comprising an amount of laquinimod and an amount of a second BDNF-increasing agent effective for use in increasing BDNF serum level in a human subject. |
申请公布号 |
US9585878(B2) |
申请公布日期 |
2017.03.07 |
申请号 |
US201012806275 |
申请日期 |
2010.08.09 |
申请人 |
TEVA PHARMACEUTICAL INDUSTRIES, LTD. |
发明人 |
Hayardeny Liat |
分类号 |
A61K31/47;A61K9/48;A61K31/4704;A61K31/138;A61K31/428;A61K9/00 |
主分类号 |
A61K31/47 |
代理机构 |
Cooper & Dunham LLP |
代理人 |
White John P.;Gershik Gary J.;Cooper & Dunham LLP |
主权项 |
1. A method for treating a human subject suffering from Huntington's disease, consisting essentially of periodically administering an amount of laquinimod or a pharmaceutically acceptable salt thereof effective to treat the human subject. |
地址 |
Petach-Tikva IL |